Form 4: Fulcrum Therapeutics Director Receives Stock Option Grant

Director Joshua Lehrer-Graiwer was granted 64,000 stock options in Fulcrum Therapeutics, Inc. as part of a standard equity incentive.

Summary

• Director Joshua Lehrer-Graiwer received a grant of 64,000 stock options on April 23, 2026.
• The options have an exercise price of $8.08 per share.
• The grant is subject to a vesting schedule of equal monthly installments over three years, concluding on April 23, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon continued service, creating a dependency on the director's ongoing relationship with the company.

Future Outlook

The options vest monthly over a three-year period, indicating a long-term retention strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized toward the company's long-term clinical and commercial success.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard equity compensation practices for board members in mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options in monthly installments through April 2029.

Key Dates

Keywords

Fulcrum Therapeutics, FULC, Form 4, Insider Trading, Stock Options, Director Compensation